Brady Family Wealth LLC cut its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 25.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 10,639 shares of the biopharmaceutical company’s stock after selling 3,702 shares during the quarter. Brady Family Wealth LLC’s holdings in Pfizer were worth $282,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in PFE. State Street Corp boosted its stake in shares of Pfizer by 1.2% in the 3rd quarter. State Street Corp now owns 290,460,600 shares of the biopharmaceutical company’s stock worth $8,405,930,000 after buying an additional 3,405,539 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Pfizer by 11.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company’s stock worth $3,766,366,000 after acquiring an additional 12,864,343 shares during the period. Geode Capital Management LLC boosted its position in Pfizer by 1.6% in the third quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company’s stock worth $3,392,342,000 after purchasing an additional 1,855,419 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Pfizer by 22.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company’s stock valued at $1,101,713,000 after purchasing an additional 6,977,587 shares during the period. Finally, Swiss National Bank increased its position in shares of Pfizer by 0.6% during the 3rd quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company’s stock valued at $486,762,000 after purchasing an additional 100,900 shares during the last quarter. 68.36% of the stock is owned by institutional investors.
Insider Buying and Selling at Pfizer
In related news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.06% of the company’s stock.
Wall Street Analyst Weigh In
Pfizer Trading Down 0.6 %
Shares of Pfizer stock opened at $26.25 on Thursday. The company’s 50-day moving average price is $26.13 and its 200-day moving average price is $28.03. The company has a market cap of $148.76 billion, a price-to-earnings ratio of 35.47, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.
Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.17) EPS. On average, equities analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.
Pfizer Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.55%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio is currently 227.03%.
Pfizer Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More
- Five stocks we like better than Pfizer
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 3 Cheap Small-Cap Banks for Dividend Growth Investors
- What Is WallStreetBets and What Stocks Are They Targeting?
- 3 Defensive Stocks Analysts Are Bullish on to Kick Off the Year
- Financial Services Stocks Investing
- Vistra Corp: Could 2025 Continue Its Streak of Outperformance?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.